Drugs / IGF-Methotrexate conjugate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02045368 | Jan 2014 → Sep 2016 | brain cancer, breast cancer, digestive system cancer, female reproductive organ cancer +2 | IGF Oncology, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGF-Methotrexate conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02045368 ↗ |
| Route | Intravenous | “765IGF-MTX is administered as an IV infusion over 1 hour” NCT02045368 ↗ |